Current status of non-transfusional haemostatic agents

Haematologica. 1999 Jun:84 Suppl EHA-4:120-3.
No abstract available

Publication types

  • Review

MeSH terms

  • Aminocaproic Acid / adverse effects
  • Aminocaproic Acid / therapeutic use
  • Antifibrinolytic Agents / administration & dosage
  • Antifibrinolytic Agents / therapeutic use
  • Aprotinin / adverse effects
  • Aprotinin / therapeutic use
  • Blood Coagulation Disorders / complications
  • Blood Coagulation Disorders / congenital
  • Blood Loss, Surgical / prevention & control
  • Cardiac Surgical Procedures
  • Contraindications
  • Deamino Arginine Vasopressin / adverse effects
  • Deamino Arginine Vasopressin / therapeutic use
  • Estrogens, Conjugated (USP) / therapeutic use
  • Hemorrhage / chemically induced
  • Hemorrhage / etiology
  • Hemostatics* / adverse effects
  • Hemostatics* / classification
  • Hemostatics* / therapeutic use
  • Humans
  • Safety
  • Tranexamic Acid / adverse effects
  • Tranexamic Acid / therapeutic use
  • Uremia / complications

Substances

  • Antifibrinolytic Agents
  • Estrogens, Conjugated (USP)
  • Hemostatics
  • Tranexamic Acid
  • Aprotinin
  • Deamino Arginine Vasopressin
  • Aminocaproic Acid